Home > > > > > Report Detail

Aplastic Anemia - Pipeline Insight, 2021

Publisher Name :
Date: 04-May-2021
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Aplastic Anemia - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Aplastic Anemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Aplastic Anemia Understanding

Aplastic Anemia: Overview

Aplastic anemia is a medical condition that damages stem cells in a person's bone marrow. These cells are responsible for making red blood cells, white blood cells, and platelets, which are vital to human health. A rare and serious condition, aplastic anemia can develop at any age. It can occur suddenly, or it can come on slowly and worsen over time. It can be mild or severe. Treatment for aplastic anemia might include medications, blood transfusions or a stem cell transplant, also known as a bone marrow transplant. The most common cause of aplastic anemia is from your immune system attacking the stem cells in your bone marrow. Other factors that can injure bone marrow and affect blood cell production include: Radiation and chemotherapy treatments, exposure to toxic chemicals, use of certain drugs, autoimmune disorders, a viral infection and unknown factors.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Aplastic Anemia R&D. The therapies under development are focused on novel approaches for Aplastic Anemia.

Aplastic Anemia Emerging Drugs Chapters

This segment of the Aplastic Anemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Aplastic Anemia Emerging Drugs

- PF-06462700: Pfizer

PF-06462700 is classified as an immunosuppressant/ immunosuppressive agent. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric immunoglobulin G (IgG), from hyperimmune serum of horses that are immunized with human thymus lymphocytes. PF-06462700 is being developed by Pfizer for Aplastic anaemia and is currently in phase III stage of development.

- REGN7257: Regeneron Pharmaceuticals

REGN7257is being developed by Regeneron Pharmaceuticals for Aplastic Anemia. It is currently in phase I/II stage of development. LB-001 acts as a modulator of Interleukin 2 and immunomodular.

Further product details are provided in the report……..

Aplastic Anemia: Therapeutic Assessment

This segment of the report provides insights about the different Aplastic Anemia drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players working on Aplastic Anemia

There are approx. 10+ key companies which are developing the Aplastic Anemia. The companies which have their Aplastic Anemia drug candidates in the most advanced stage, i.e. Phase III include, Pfizer.

- Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

- Late-stage products (Phase III and

- Mid-stage products (Phase II and

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Aplastic Anemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Infusion

- Intradermal

- Intramuscular

- Intranasal

- Intravaginal

- Oral

- Parenteral

- Subcutaneous

- Topical

- Molecule Type

Products have been categorized under various Molecule types such as

- Vaccines

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Aplastic Anemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Aplastic Anemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aplastic Anemia drugs.

Aplastic Anemia Report Insights

- Aplastic Anemia Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Aplastic Anemia Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

- How many companies are developing Aplastic Anemia drugs?

- How many Aplastic Anemia drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for Aplastic Anemia?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Aplastic Anemia therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Aplastic Anemia and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Pfizer

- Regeneron Pharmaceuticals

- Regen BioPharma

- Omidubicel

- Cellenkos

- Hemogenyx

Key Products

- PF-06462700

- REGN7257

- HemaXellerate

- Gamida Cell

- CK-0801

- Hu PHEC

?

Aplastic Anemia - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
Aplastic Anemia: Overview
* Structure
* Mechanism of Action
Pipeline Therapeutics
* Comparative Analysis
Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
Aplastic Anemia- DelveInsight's Analytical Perspective
In-depth Commercial Assessment
* Aplastic Anemia companies' collaborations, Licensing, Acquisition -Deal Value Trends
Aplastic Anemia Collaboration Deals
* Company-Company Collaborations (Licensing / Partnering) Analysis
* Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
* Comparative Analysis
PF-06462700: Pfizer
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
* Comparative Analysis
Drug Name: Company Name
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
* Comparative Analysis
Omidubicel: Gamida Cell
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
* Comparative Analysis
Hu-PHEC: Hemogenyx
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..

Inactive Products
* Comparative Analysis
Aplastic Anemia Key Companies
Aplastic Anemia Key Products
Aplastic Anemia- Unmet Needs
Aplastic Anemia- Market Drivers and Barriers
Aplastic Anemia- Future Perspectives and Conclusion
Aplastic Anemia Analyst Views
Aplastic Anemia Key Companies
Appendix

List of Tables

Table 1 Total Products for Aplastic Anemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Aplastic Anemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Erythropoietin Stimulating Agents Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 02-Jan-2024        Price: US 3380 Onwards        Pages: 113
    Market Overview of Global Erythropoietin Stimulating Agents market: According to our latest research, the global Erythropoietin Stimulating Agents market looks promising in the next 5 years. As of 2022, the global Erythropoietin Stimulating Agents market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Red blood cells are produced in the bone marrow (the spongy tissue inside the bone). In orde......
  • Global Erythropoietin Stimulating Agents Professional Survey Report 2023, Forecast to 2028
    Published: 13-Dec-2023        Price: US 3280 Onwards        Pages: 105
    Erythropoiesis-stimulating agent - Wikipediaen.wikipedia.org › wiki › Erythropoiesis-stimulating_a... Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market cap......
  • Global Erythropoietin Stimulating Agents Market Research Report 2023, Forecast to 2028
    Published: 13-Dec-2023        Price: US 2680 Onwards        Pages: 131
    Erythropoiesis-stimulating agent - Wikipediaen.wikipedia.org › wiki › Erythropoiesis-stimulating_a... Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market cap......
  • Global Erythropoietin Stimulating Agents Market Research Report 2023
    Published: 06-Dec-2023        Price: US 2900 Onwards        Pages: 92
    Erythropoiesis-stimulating agents (ESA) are medications which stimulate the bone marrow to make red blood cells. They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS. According to QYResearch's new survey, global Erythropoietin Stimulating Agents market is projected to reach US$ 12520 million in 2029, increasing from US$ 8939 million in 2022, with the CAGR of 4.2% during the period of 2023 to 2029. Key companie......
  • Global Erythropoietin Stimulating Agents Market Insights, Forecast to 2029
    Published: 02-Aug-2023        Price: US 4900 Onwards        Pages: 107
    Erythropoiesis-stimulating agents (ESA) are medications which stimulate the bone marrow to make red blood cells. They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS. Market Analysis and Insights: Global Erythropoietin Stimulating Agents Market The global Erythropoietin Stimulating Agents market is projected to grow from US$ 5779 million in 2023 to US$ 6244.6 million by 2029, at a Compound Annual Growth Rate (......
  • Global Erythropoietin Stimulating Agents Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 28-Feb-2023        Price: US 3260 Onwards        Pages: 128
    Erythropoietin is a hormone released the human renal system (kidney) which increases the rate of production of red blood cells in response to falling levels of oxygen in the tissues and helps in the process of erythropoiesis (production of red blood cells). Erythropoietin stimulating agents (EPO) are used to treat people undergone chemotherapy or treatments related to HIV. The Erythropoietin Stimulating Agents market revenue was XX Million USD in 2022, and will reach XX Million USD in 202......
  • Global Erythropoietin Stimulating Agents Market Research Report 2022 - Market Size, Current Insights and Development Trends
    Published: 01-Dec-2022        Price: US 3450 Onwards        Pages: 124
    Red blood cells are produced in the bone marrow (the spongy tissue inside the bone). In order to make red blood cells, the body maintains an adequate supply of erythropoietin (EPO), a hormone that is produced by the kidney. EPO helps make red blood cells. Having more red blood cells raises your hemoglobin levels. Hemoglobin is the protein in red blood cells that helps blood carry oxygen throughout the body. The report focuses on the Erythropoietin Stimulating Agents market size, s......
  • Global Erythropoietin Stimulating Agents Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
    Published: 21-Nov-2022        Price: US 5600 Onwards        Pages: 106
    Report Scope This latest report researches the industry structure, revenue and gross margin. Major players' headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Erythropoietin Stimulating Agents companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, ......
  • Global Erythropoietin Stimulating Agents Market Research Report 2022
    Published: 25-Jul-2022        Price: US 2900 Onwards        Pages: 91
    Erythropoietin Stimulating Agents market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Erythropoietin Stimulating Agents market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - Epoetin Alfa - Epoetin Beta - Darbepoetin ......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs